Liquid Biopsy



CancerPathwayFinder_700x233

ncRNAs as circulating cancer biomarkers for liquid biopsy

Cancer biomarkers are critical at multiple points during the disease process. Novel biomarkers for cancer screening, obtained via liquid biopsies, would be of particular clinical value given the difficulty of early detection for lethal malignancies such as ovarian and pancreatic cancer. Even cancers that are easily detected could benefit from improved screening and staging methods…. Read article →


microRNA and lncRNA in lung cancer

miRNA and lncRNA – serum biomarkers for lung cancer

One of the most exciting potential applications of circulating non-coding RNAs like microRNA (miRNA) and long non-coding RNA (lncRNA) is as biomarkers for early detection of cancer. Cancer treatment, like treatment of many other diseases, can be far more effective when started early. Easily accessible markers like RNAs in the blood are an attractive possibility for finding… Read article →


next-generation sequencing

From sample to insight: NGS for liquid biopsy and beyond

The use of high-throughput next-generation sequencing (NGS) technologies continues to provide a wealth of sequence data, resulting in significant advances in a wide range of research areas and applications. Key among these is liquid biopsy – the ability to sequence nucleic acids found in circulation will enable scientists to identify key mutations and more specifically distinguish… Read article →